Lipid modification - CVD prevention
Exam Tips
- For UK exams, remember non-fasting lipid sampling is acceptable and non-HDL is central for monitoring response.
- Primary prevention target in NICE-style practice: >40% fall in non-HDL cholesterol after starting statin.
- Do not rely only on QRISK3 when risk may be underestimated (e. g. HIV, severe mental illness, inflammatory disease, drug-induced dyslipidaemia).
- Know key statin safety points: avoid in pregnancy and breastfeeding, caution/avoid in active liver disease, review interactions, and investigate muscle symptoms with CK when clinically indicated.
- Type 1 diabetes, CKD, and familial hypercholesterolaemia are high-risk groups where statin decisions may not require standard risk-score thresholds.
Definition
Lipid modification for CVD prevention is the structured reduction of atherogenic lipoprotein burden (especially non-HDL and LDL cholesterol) to lower first and recurrent cardiovascular events. In UK practice it combines risk stratification (for example QRISK3), lifestyle intervention, and evidence-based lipid-lowering therapy, with treatment intensity matched to baseline risk and comorbidity.
Pathophysiology
Atherosclerotic CVD is driven by retention of apoB-containing lipoproteins (mainly LDL and remnant particles) in the arterial intima, causing endothelial dysfunction, oxidation, monocyte recruitment, foam-cell formation, and progressive plaque growth. Plaque inflammation and fibrous cap weakening can culminate in rupture or erosion with thrombosis, producing MI, stroke, or acute limb events. Non-HDL cholesterol is clinically useful because it captures all atherogenic particles (not just LDL), so residual risk may persist despite acceptable LDL alone. Triglyceride-rich lipoproteins and low HDL often mark higher cardiometabolic risk. Image reference: see standard atherosclerotic plaque progression figure in core cardiology/pathology textbooks.
Risk Factors
- Year QRISK3 score >=10%
- Type 2 diabetes mellitus
- Type 1 diabetes (especially age >40 years, duration >10 years, nephropathy, or additional CVD risk factors)
- Chronic kidney disease (eGFR <60 mL/min/1.73 m2 and/or albuminuria)
- Familial hypercholesterolaemia or other inherited dyslipidaemia
- Age >=85 years (especially with smoking or hypertension)
- Smoking (including recent smoking cessation period where risk remains elevated)
- Hypertension, obesity, sedentary lifestyle, poor diet
- Severe mental illness and chronic inflammatory/autoimmune disorders
- HIV and/or medicines that worsen lipids (e. g. antipsychotics, corticosteroids, immunosuppressants)
Clinical Features
Symptoms
- Usually none (dyslipidaemia is often asymptomatic)
- Symptoms may reflect occult/established CVD: exertional chest pain, transient neurological deficit, or exertional calf pain
Signs
- Often no abnormal findings on examination
- Possible lipid disorder stigmata: tendon xanthomas, xanthelasma, premature corneal arcus (especially in inherited disorders)
- Signs of target-organ vascular disease if present (e. g. reduced peripheral pulses, carotid bruit)
Investigations
Management
Lifestyle Modifications
- Heart-healthy diet (Mediterranean-style pattern, reduced saturated/trans fats, higher fibre, oily fish, plant-based fats)
- Regular physical activity (at least 150 minutes/week moderate intensity or 75 minutes vigorous, plus strength work)
- Smoking cessation support and relapse prevention
- Weight reduction where overweight/obese and optimisation of BP/glycaemic control
- Address alcohol excess and offer structured behavioural support/referral programmes
Pharmacological Treatment
Statin (first-line primary prevention)
- Atorvastatin 20 mg once daily
Offer for QRISK3 >=10% and in high-risk groups (e. g. CKD, many with diabetes, familial dyslipidaemia) after shared decision-making. If QRISK3 <10%, may still be reasonable if risk is underestimated or patient preference is strong.
Alternative statins (if intolerance/interactions)
- Rosuvastatin 10 mg once daily
- Simvastatin 20-40 mg once daily (interaction-prone)
Use lower-intensity or alternative statin if adverse effects occur; check interaction profile carefully (notably with macrolides, azole antifungals, ciclosporin, some calcium-channel blockers, HIV therapies, grapefruit with simvastatin/atorvastatin).
Cholesterol absorption inhibitor
- Ezetimibe 10 mg once daily
Consider if statin is contraindicated/not tolerated, or as add-on when lipid response is inadequate despite adherence.
Complications
- Coronary heart disease (stable angina, acute coronary syndrome, myocardial infarction)
- Cerebrovascular disease (TIA, ischaemic stroke)
- Peripheral arterial disease and critical limb ischaemia
- Aortic atherosclerotic disease
- Medication-related harms: myalgia/myopathy, rare rhabdomyolysis, transaminitis, small increase in incident diabetes risk with statins
Prognosis
Without treatment, persistent atherogenic dyslipidaemia increases lifetime ASCVD risk. Prognosis improves substantially with sustained lifestyle change and adherence to lipid-lowering therapy; greater non-HDL/LDL reduction is associated with larger reductions in major vascular events. In primary prevention, achieving >40% non-HDL reduction is a practical UK target linked to meaningful risk reduction.
Sources & References
✅NICE Guidelines(1)
- Lipid modification - CVD prevention[overview]
📖Textbook References(3)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 883)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 882, 883)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 883)[context]